Ian Chau

Ian Chau publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ian Chau sits on this spectrum.

Ian Chau D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ian Chau sits on this spectrum.

Overview

Best Publications

• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  David Cunningham;Yves Humblet;Salvatore Siena;David Khayat

  6467
  Citations

• Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

  Julie R. Brahmer;Christina Lacchetti;Bryan J. Schneider;Michael B. Atkins

  3808
  Citations

• Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

  Charles S Fuchs;Jiri Tomasek;Cho Jae Yong;Filip Dumitru

  2609
  Citations

• Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

  David M. Hyman;Igor Puzanov;Vivek Subbiah;Jason E. Faris

  1804
  Citations

• Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

  Georgios Vlachogiannis;Somaieh Hedayat;Alexandra Vatsiou;Yann Jamin

  1554
  Citations

• Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

  Scott J. Antonia;José A. López-Martin;Johanna Bendell;Patrick A. Ott

  1382
  Citations

• Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

  Kohei Shitara;Mustafa Özgüroğlu;Yung-Jue Bang;Maria Di Bartolomeo

  1294
  Citations

• Ramucirumab Versus Placebo as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH): A Randomised, Double-Blind, Multicentre, Phase 3 Trial

  Andrew X. Zhu;Joon Oh Park;Baek Yeol Ryoo;Chia Jui Yen

  974
  Citations

• Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

  David Cunningham;Ian Chau;Deborah D. Stocken;Juan W. Valle

  965
  Citations

• Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

  Tom Waddell;Ian Chau;David Cunningham;David Gonzalez

  889
  Citations

• FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

  Mustafa Suker;Berend R Beumer;Eran Sadot;Lysiane Marthey

  882
  Citations

• Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer—Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient Data

  Ian Chau;Andy R. Norman;David Cunningham;Justin S. Waters

  684
  Citations

• Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02) : an open-label, phase 3 randomised controlled trial

  Hugo E R Ford;Andrea Marshall;John A Bridgewater;Tobias Janowitz

  662
  Citations

• Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.

  Bryan J Schneider;Jarushka Naidoo;Bianca D Santomasso;Christina Lacchetti

  563
  Citations

• CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

  Yelena Y. Janjigian;Johanna Bendell;Emiliano Calvo;Joseph W. Kim

  548
  Citations

• Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging–Defined Poor-Risk Rectal Cancer

  Ian Chau;Gina Brown;David Cunningham;Diana Tait

  540
  Citations

• Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C)

  Alice Dewdney;David Cunningham;Josep Tabernero;Jaume Capdevila

  487
  Citations

• Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.

  Matthew T Seymour;Sarah R Brown;Gary Middleton;Timothy Maughan

  484
  Citations

• First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

  Harpreet S Wasan;Peter Gibbs;Navesh K Sharma;Julien Taieb

  383
  Citations

• Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial

  Yu Jo Chua;Yu Jo Chua;Yolanda Barbachano;David Cunningham;Jacqui R Oates

  377
  Citations